Burning Rock Dx(US:BNR) Jin Rong Jie·2025-08-19 13:49Core Viewpoint - BNR (Burning Stone Medical) shows a significant increase in stock price and positive financial growth, indicating a strong position in the precision oncology market [1][2]. Financial Performance - As of March 31, 2025, BNR reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94% [1]. - The company recorded a net profit attributable to shareholders of -13.5 million RMB, which is an improvement with a year-on-year growth of 88.89% [1]. Major Events - BNR is scheduled to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual date subject to company announcement [1]. Company Background - Founded in 2014, BNR focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [1]. - The company has a leading market share in tumor patient testing in China and collaborates with global anti-tumor pharmaceutical companies on biomarkers and companion diagnostics [1]. - BNR has achieved significant milestones, including receiving the first NGS testing kit certification from the National Medical Products Administration (NMPA) in China in July 2018 [2]. - The laboratories in Guangzhou and California have obtained quality system certifications from CLIA and CAP, ensuring high standards in their testing processes [2].